Value of PD-1 and PD-L1 expression in predicting immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer patients
Objective To explore the value of programmed death receptor 1 (PD-1) and programmed death receptor ligand 1 (PD-L1) expression in predicting immune checkpoint inhibitor-associated pneumonia (CIP) in non-small cell lung cancer (NSCLC) patients.Methods Clinical data of 100 NSCLC patients who received immunotherapy at the First Affiliated Hospital of Wenzhou Medical University from January 2022 to June 2023 were retrospectively analyzed,among whom CIP developed in 31 cases (CIP group) and did not develop in 69 cases (non-CIP group).The expression levels of PD-1 and PD-L1 in the serum of patients were measured using ELISA method and compared between two groups.The independent risk factors for CIP in NSCLC patients were identified by multiple logistic regression analysis,and the value of PD-1 and PDL1 expression in predicting CIP was analyzed with ROC curve.Results The expression levels of serum PD-1 and PD-L1 in CIP group were significantly higher than those in non-CIP group (both P<0.05).ROC curve analysis showed that the sensitivity and specificity of PD-1 in predicting CIP in NSCLC patients were 0.774 and 0.710,respectively;those of PD-L1 were 0.681 and 0.884,respectively.Multivariate logistic regression analysis showed that age,smoking history,baseline lung function,history of lung radiation therapy,PD-1 and PD-L1 expression were independent risk factors for developing CIP in NSCLC patients (all P<0.05).Conclusion Higher expression levels of serum PD-1 and PD-L1 are independent risk factors for the occurrence of CIP in NSCLC patients,which may be used to predict CIP in NSCLC patients clinically.
Programmed death receptor 1Programmed death receptor ligand 1Non-small cell lung cancerImmune checkpoint inhibitor-associated pneumonia